Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
2(20%)
Results Posted
160%(8 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_3
1
10%
Ph phase_1
1
10%
Ph phase_2
6
60%
Ph phase_4
2
20%

Phase Distribution

1

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2
Not yet recruiting1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 26 (60.0%)
Phase 31 (10.0%)
Phase 42 (20.0%)

Trials by Status

not_yet_recruiting110%
active_not_recruiting110%
completed550%
recruiting110%
terminated220%

Recent Activity

2 active trials
Showing 5 of 10
recruitingphase_3

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
terminatedphase_2

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

NCT06365437
active_not_recruitingphase_2

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411
not_yet_recruitingphase_2

VEL-101 to Prevent Rejection After Kidney Transplantation

NCT07290777
completedphase_2

A Dose Escalation Study in de Novo Renal Transplantation

NCT04311632
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06615050Phase 3

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Recruiting
NCT06365437Phase 2

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Terminated
NCT03674411Phase 2

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active Not Recruiting
NCT07290777Phase 2

VEL-101 to Prevent Rejection After Kidney Transplantation

Not Yet Recruiting
NCT04311632Phase 2

A Dose Escalation Study in de Novo Renal Transplantation

Completed
NCT02217410Phase 1

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Completed
NCT01713400Phase 2

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

Completed
NCT00862979Phase 4

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

Completed
NCT00166712Phase 4

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

Terminated
NCT00803010Phase 2

Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10